Single Blog

NEO-201: A Next-Generation Neoepitope-Targeting Cancer Antibody

NEO-201 is an investigational monoclonal antibody designed to recognize tumor-associated neoepitopes—abnormal O-glycan and glycoprotein structures preferentially displayed on the surface of malignant cells while being largely absent from healthy tissues. By homing in on these cancer-selective carbohydrate signatures, NEO-201 aims to direct the immune system to attack tumors with far greater precision than conventional chemotherapy, which often damages any rapidly dividing cell.

As part of the emerging class of neoepitope-targeting biologics, NEO-201 sits at the cutting edge of immuno-oncology, where glycoproteomics, precision biomarkers, and AI-driven target discovery are converging to reshape how we treat solid tumors
(doi:10.1158/2326-6066.CIR-20-0931).

How Does NEO-201 Work at the Tumor–Immune Interface?

Selective Binding to Tumor-Associated O-Glycans

NEO-201 was engineered to bind selectively to aberrant mucin-type O-glycans and related glyco-epitopes that are overexpressed in colorectal, pancreatic, ovarian, and other epithelial cancers. These neoepitopes arise from cancer-driven changes in glycosylation pathways, creating “non-self” patterns on the tumor cell surface that can be exploited as immune targets
(doi:10.3390/cancers15174420).

Antibody-Dependent Cellular Cytotoxicity (ADCC)

Once NEO-201 binds to its target on a tumor cell, the Fc portion of the antibody is recognized by Fc-gamma receptors on immune effector cells—especially natural killer (NK) cells. This interaction triggers antibody-dependent cellular cytotoxicity (ADCC), leading to:

• Directed killing of neoepitope-positive tumor cells
• Amplification of immune responses through cytokine release and recruitment of additional effector cells
• Potential reshaping of the tumor microenvironment to become more inflamed and immunologically “visible”
  (doi:10.1158/2326-6066.CIR-20-0931)

Synergy with Checkpoint Inhibitors and Other IO Agents

Because NEO-201 directly labels tumor cells for immune attack, it may synergize with PD-1/PD-L1 or CTLA-4 inhibitors that release systemic immune brakes. Early translational research suggests that combining neoepitope-targeting antibodies with checkpoint blockade or NK cell–activating agents could overcome resistance seen with single-agent immunotherapies.

Why NEO-201 Is Capturing Attention in Oncology

Aligning with Precision and Biomarker-Driven Medicine

NEO-201 development is tightly linked to biomarker strategies. Patients are selected based on high expression of the NEO-201 target epitope, aligning with precision oncology principles where:

• Patient selection is guided by tumor glycoprofiling
• Response prediction leverages neoepitope density and distribution
• AI tools may refine which glycan patterns best predict benefit
  (doi:10.3390/cancers15174420)

First-in-Human Data: Proof of Concept

In a first-in-human phase I trial enrolling patients with advanced solid tumors, NEO-201 demonstrated a manageable safety profile and early signals of antitumor activity, including disease stabilization in heavily pretreated patients
(doi:10.1158/2326-6066.CIR-20-0931). While preliminary, these data validate tumor binding, immune engagement, and the feasibility of targeting glyco-neoepitopes in the clinic.

Potential Clinical Applications and Combination Strategies

Based on its epitope profile and preclinical data, NEO-201 is being explored or proposed for:

• Metastatic colorectal cancer after exhaustion of standard chemotherapy and biologics
• Pancreatic ductal adenocarcinoma, where immunotherapy options remain limited and outcomes poor
• Ovarian and endometrial cancers that frequently overexpress abnormal mucin-type O-glycans
  (doi:10.3390/cancers15174420)

Future directions include pairing NEO-201 with:

• Checkpoint inhibitors to deepen and prolong responses
• NK cell–expanding or –priming agents to boost ADCC
• Antibody–drug conjugate (ADC) payloads to deliver cytotoxics directly to neoepitope-positive cells

Safety, Challenges, and the Road Ahead

On-Target, Off-Tumor Risks and Tumor Heterogeneity

Key challenges for NEO-201 include:

• On-target, off-tumor toxicity: Even low-level expression of target epitopes in normal tissues could cause collateral damage.
• Intratumoral heterogeneity: Not every cancer cell within a tumor may express the neoepitope, creating niches for immune escape.
• Manufacturing complexity: Producing antibodies with highly specific glyco-epitope recognition at scale demands advanced bioprocessing and analytics.

From Neoepitope Mapping to AI-Guided Patient Selection

As clinical trials progress, sophisticated glycoproteomic profiling and AI-driven epitope mapping are expected to refine which patients benefit most from NEO-201. Integrating digital pathology, mass spectrometry, and machine learning could enable:

• More accurate prediction of responders
• Dynamic monitoring of epitope loss and resistance
• Rational design of next-generation neoepitope-targeting antibodies

NEO-201 thus represents more than a single drug candidate; it is a test case for a broader paradigm in oncology—using tumor-specific glycan signatures as precision immunotherapy targets
(doi:10.1158/2326-6066.CIR-20-0931;
doi:10.3390/cancers15174420).

References

• Peguero J, et al. First-in-human study of NEO-201, a novel tumor-associated antigen targeting monoclonal antibody, in advanced solid tumors. Cancer Immunol Res. 2021;9(12):1442–1453.
  doi:10.1158/2326-6066.CIR-20-0931
• Posey AD Jr, et al. Targeting tumor-associated O-glycans in solid cancers: from neoepitopes to next-generation immunotherapies. Cancers (Basel). 2023;15(17):4420.
  doi:10.3390/cancers15174420